Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Matrixport: Bitcoin Narrow Volatility Drives Sell Option Strategies, Volatility Expected to Continue Declining

Matrixport: Bitcoin Narrow Volatility Drives Sell Option Strategies, Volatility Expected to Continue Declining

Bitget2024/09/24 07:28

According to Bitget, Matrixport pointed out in its latest report: "Although Bitcoin is inherently volatile, the 30-day rolling return rate shows that its price has basically remained within a +20% fluctuation range over the past 18 months. We expect volatility to further decrease, so we suggest adopting a sell option strategy at the beginning of 2023, including selling out-of-the-money put and call options for additional income. Even though this strategy may result in losses, it still performs well overall as volatility decreases. With the introduction of Bitcoin ETF-related options, more institutional participants are expected to enter the market and further compress volatility. Therefore, selling volatility remains a viable strategy for Bitcoin holders to earn extra income."

News Image 0
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.